# US 2026/0083709 A1 · Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083709 A1
- Document ID: US20260083709A1
- Status: Published application
- Kind: A1
- Application number: 19/407,061
- Filed: 2025-12-03
- Published: 2026-03-26
- Earliest claimed: 2019-11-04
- Assignees: Apnimed, Inc. (Delaware); Brigham and Women' Hospital
- Applicants: Apnimed, Inc.(Delaware); The Brigham and Women' Hospital, Inc.
- Inventors: Lawrence G. MILLER; Ronald FARKAS; D. Andrew WELLMAN; Luigi TARANTO-MONTEMURRO; Scott Aaron SANDS
- Web page: https://patentgrep.com/patent/US20260083709A1

## CPC

- A61K 31/433: Thidiazoles
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In general, the invention relates to pharmaceutical compositions comprising a norepinephrine reuptake inhibitor (NRI), muscarinic receptor antagonist, and carbonic anhydrase inhibitor and methods of treating Sleep Apnea comprising the administration of these pharmaceutical compositions.

## Claims

### Claim 1

A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI); (ii) a muscarinic receptor antagonist; and (iii) a carbonic anhydrase inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the carbonic anhydrase inhibitor is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, and any combination thereof.

### Claim 3 (depends on 1, 2)

The method of either of claims 1 or 2, wherein the carbonic anhydrase inhibitor is acetazolamide.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 5 (depends on 4)

The method of claim 4, wherein the NRI is Atomoxetine.

### Claim 6 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 7 (depends on 6)

The method of claim 6, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

### Claim 8 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the muscarinic receptor antagonist comprises oxybutynin.

### Claim 10 (depends on 9)

The method of claim 9, wherein the oxybutynin is a substantially pure (R)-oxybutynin.

### Claim 11 (depends on 9)

The method of claim 9, wherein the oxybutynin is a racemic mixture of (R)-oxybutynin and (S)-oxybutynin.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the carbonic anhydrase inhibitor, such as acetazolamide, is administered at a dosage of from about 250 mg to about 750 mg.

### Claim 13 (depends on 12)

The method of claim 12, wherein the carbonic anhydrase inhibitor, such as acetazolamide, is administered at a dosage of about 500 mg.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the NRI, such as atomoxetine, is administered at a dosage of from about 20 to about 150 mg.

### Claim 15 (depends on 14)

The method of claim 14, wherein the NRI, such as atomoxetine, is administered at a dosage of from about 50 to about 100 mg.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the muscarinic receptor antagonist, such as oxybutynin, is administered at a dosage of from about 1 to about 15 mg.

### Claim 17 (depends on 16)

The method of claim 16, wherein the muscarinic receptor antagonist, such as oxybutynin, is administered at a dosage of from about 2.5 to about 7.5 mg.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the condition associated with pharyngeal airway collapse is Sleep Apnea or Simple Snoring.

### Claim 19 (depends on 18)

The method of claim 18, wherein the condition associated with pharyngeal airway collapse is Obstructive Sleep Apnea (OSA).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the subject is in a non-fully conscious state.

### Claim 21 (depends on 20)

The method of claim 20, wherein the non-fully conscious state is sleep.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the NRI, muscarinic receptor antagonist, and carbonic anhydrase inhibitor are administered in a single composition.

### Claim 23 (depends on 22)

The method of claim 22, wherein the single composition is an oral administration form.

### Claim 24 (depends on 23)

The method of claim 23, wherein the oral administration form is a syrup, pill, tablet, troche, capsule, or patch.

### Claim 25

A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI); (ii) a muscarinic receptor antagonist; and (iii) a carbonic anhydrase inhibitor, in a pharmaceutically acceptable carrier.

### Claim 26 (depends on 25)

The composition of claim 25, wherein the carbonic anhydrase inhibitor is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, and any combinations thereof.

### Claim 27 (depends on 25, 26)

The composition of either of claims 25 or 26, wherein the carbonic anhydrase inhibitor is acetazolamide.

### Claim 28 (depends on 25, 26, 27)

The composition of any one of claims 25-27, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the NRI is Atomoxetine.

### Claim 30 (depends on 25, 26, 27)

The composition of any one of claims 25-27, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

### Claim 31 (depends on 30)

The composition of claim 30, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

### Claim 32 (depends on 25, 26, 27)

The composition of any one of claims 25-27, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

### Claim 33 (depends on 25, 26, 27, 28, 29, 30, 31, 32)

The composition of any one of claims 25-32, wherein the muscarinic receptor antagonist comprises oxybutynin.

### Claim 34 (depends on 33)

The composition of claim 33, wherein the oxybutynin is a substantially pure (R)-oxybutynin.

### Claim 35 (depends on 33)

The composition of claim 33, wherein the oxybutynin is a racemic mixture of (R)-oxybutynin and (S)-oxybutynin.

### Claim 36 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The composition of any one of claims 25-35, wherein the carbonic anhydrase inhibitor, such as acetazolamide, is present in an amount of from about 250 mg to about 750 mg.

### Claim 37 (depends on 36)

The composition of claim 36, wherein the carbonic anhydrase inhibitor, such as acetazolamide, is present in an amount of about 500 mg.

### Claim 38 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The composition of any one of claims 25-37, wherein the NRI, such as atomoxetine, is present in an amount of from about 20 to about 150 mg.

### Claim 39 (depends on 38)

The composition of claim 38, wherein the NRI, such as atomoxetine, is present in an amount of from about 50 to about 100 mg.

### Claim 40 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The composition of any one of claims 25-39, wherein the muscarinic receptor antagonist, such as oxybutynin, is present in an amount of from about 1 to about 15 mg.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the muscarinic receptor antagonist, such as oxybutynin, is present in an amount of from about 2.5 to about 7.5 mg.

### Claim 42 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The composition of any one of claims 25-41, wherein the pharmaceutical formulation is in an immediate release formulation.

### Claim 43 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The composition of any one of claims 25-41, wherein the pharmaceutical formulation is in an extended release formulation.

### Claim 44 (depends on 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The composition of any one of claims 25-43, for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 45 (depends on 44)

The composition for use of claim 44, wherein the condition associated with pharyngeal airway collapse is Sleep Apnea or Simple Snoring.

### Claim 46 (depends on 45)

The composition for use of claim 45, wherein the condition associated with pharyngeal airway collapse is Obstructive Sleep Apnea (OSA).

### Claim 47 (depends on 44, 45, 46)

The composition for use of any one of claims 44-46, wherein the subject is in a non-fully conscious state.

### Claim 48 (depends on 47)

The composition for use of claim 47, wherein the non-fully conscious state is sleep.

### Claim 49

A norepinephrine reuptake inhibitor (NRI), a muscarinic receptor antagonist, and a carbonic anhydrase inhibitor for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 50

A kit comprising a norepinephrine reuptake inhibitor (NRI), a muscarinic receptor antagonist, and a carbonic anhydrase inhibitor.

### Claim 51 (depends on 50)

The kit of claim 50, for use in treating a subject having a condition associated with pharyngeal airway collapse.

### Claim 52

A method of treating a subject having a condition associated with pharyngeal airway collapse, the method comprising administering to a subject in need thereof an effective amount of (i) Atomoxetine; (ii) Oxybutynin; and (iii) Acetazolamide.

### Claim 53

A pharmaceutical composition comprising (i) Atomoxetine; (ii) Oxybutynin; and (iii) Acetazolamide, in a pharmaceutically acceptable carrier.

### Claim 54

A method for lowering loop gain and increasing muscle responsiveness in a subject having obstructive sleep apnea (OSA), the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI); (ii) a muscarinic receptor antagonist; and (iii) a carbonic anhydrase inhibitor.

### Claim 55 (depends on 54)

The method of claim 54, wherein the carbonic anhydrase inhibitor is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, and any combinations thereof.

### Claim 56 (depends on 54, 55)

The method of either of claims 54 or 55, wherein the carbonic anhydrase inhibitor is acetazolamide.

### Claim 57 (depends on 54, 55, 56)

The method of any one of claims 54-56, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 58 (depends on 54, 55, 56, 57)

The method of any one of claims 54-57, wherein the NRI is Atomoxetine.

### Claim 59 (depends on 54, 55, 56, 57, 58)

The method of any one of claims 54-58, wherein the muscarinic receptor antagonist comprises oxybutynin.

### Claim 60 (depends on 59)

The method of claim 59, wherein the oxybutynin is a substantially pure (R)-oxybutynin.

### Claim 61 (depends on 59)

The method of claim 59, wherein the oxybutynin is a racemic mixture of (R)-oxybutynin and (S)-oxybutynin.

### Claim 62 (depends on 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 54-61, wherein the condition associated with pharyngeal airway collapse is Sleep Apnea or Simple Snoring.

### Claim 63 (depends on 62)

The method of claim 62, wherein the condition associated with pharyngeal airway collapse is Obstructive Sleep Apnea (OSA).

### Claim 64 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the subject is in a non-fully conscious state.

### Claim 65 (depends on 64)

The method of claim 64, wherein the non-fully conscious state is sleep.

### Claim 66 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 54-65, wherein the NRI, muscarinic receptor antagonist, and carbonic anhydrase inhibitor are administered in a single composition.

### Claim 67 (depends on 66)

The method of claim 66, wherein the single composition is an oral administration form.

### Claim 68 (depends on 67)

The method of claim 67, wherein the oral administration form is a syrup, pill, tablet, troche, capsule, or patch.

### Claim 69

A method for lowering loop gain and increasing muscle responsiveness in a subject having obesity hypoventilation syndrome (OHS), the method comprising administering to a subject in need thereof an effective amount of (i) a norepinephrine reuptake inhibitor (NRI); (ii) a muscarinic receptor antagonist; and (iii) a carbonic anhydrase inhibitor.

### Claim 70 (depends on 69)

The method of claim 69, wherein the carbonic anhydrase inhibitor is selected from the group consisting of acetazolamide, dichlorophenamide, dorzolamide, brinzolamide, methazolamide, zonisamide, ethoxzolamide, topiramate, sultiame, and any combinations thereof.

### Claim 71 (depends on 69, 70)

The method of either of claims 69 or 70, wherein the carbonic anhydrase inhibitor is acetazolamide.

### Claim 72 (depends on 69, 70, 71)

The method of any one of claims 69-71, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

### Claim 73 (depends on 69, 70, 71, 72)

The method of any one of claims 69-72, wherein the NRI is Atomoxetine.

### Claim 74 (depends on 69, 70, 71, 72, 73)

The method of any one of claims 69-73, wherein the muscarinic receptor antagonist comprises oxybutynin.

### Claim 75 (depends on 74)

The method of claim 74, wherein the oxybutynin is a substantially pure (R)-oxybutynin.

### Claim 76 (depends on 74)

The method of claim 74, wherein the oxybutynin is a racemic mixture of (R)-oxybutynin and (S)-oxybutynin.

### Claim 77 (depends on 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 69-76, wherein the subject has both obesity hypoventilation syndrome (OHS) and obstructive sleep apnea (OSA).

### Claim 78 (depends on 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 69-77, wherein the NRI, muscarinic receptor antagonist, and carbonic anhydrase inhibitor are administered in a single composition.

### Claim 79 (depends on 78)

The method of claim 78, wherein the single composition is an oral administration form.

### Claim 80 (depends on 79)

The method of claim 79, wherein the oral administration form is a syrup, pill, tablet, troche, capsule, or patch.
